成人2型糖尿病中的持续葡萄糖监测:系统综述与Meta分析
该系统综述与Meta分析纳入12项RCT共1248例成人2型糖尿病患者,比较持续葡萄糖监测(CGM)与自我血糖监测(SMBG)。CGM使HbA1c平均降低3.43 mmol/mol(0.31%),并改善范围内时间等指标;严重低血糖与大血管并发症发生率无统计学显著差异,微血管并发症无数据。所有研究均为开放标签,严重低血糖及并发症数据稀缺。
要点
- CGM较SMBG使成人2型糖尿病患者HbA1c平均降低3.43 mmol/mol(0.31%)。
- CGM使范围内时间增加6.36%,低于范围时间降低0.66%。
- 严重低血糖与大血管并发症发生率无统计学显著差异,微血管并发症无数据。
核心结论
- 在成人2型糖尿病患者中,与SMBG相比,使用CGM与血糖控制改善相关。
- 然而所有研究均为开放标签,且严重低血糖及微血管和大血管并发症的发生数据稀缺。
研究设计与样本
- 系统综述与Meta分析,检索Embase、MEDLINE、Web of Science、Scopus和ClinicalTrials.gov自建库至2023年5月2日。
- 纳入比较实时CGM(rtCGM)或间歇扫描式CGM(isCGM)与SMBG的RCT,干预时长<6周、专业CGM、CGM联合额外降糖治疗策略或GlucoWatch的研究不合格。
- 共纳入12项RCT、1248例参与者,其中8项研究rtCGM、4项研究isCGM。
- 使用Cochrane偏倚风险工具版本2评估偏倚风险,并通过Meta分析合成数据。
- 该系统综述在PROSPERO注册(ID CRD42023418005)。
主要发现
- 与SMBG相比,CGM(rtCGM或isCGM)使HbA1c平均差异(MD)为-3.43 mmol/mol(-0.31%;95%CI -4.75, -2.11,p<0.00001,I²=15%;中等确定性)。
- 在使用胰岛素联合或不联合口服药者中MD为-3.27 mmol/mol(-0.30%;95%CI -6.22, -0.31,p=0.03,I²=55%),在仅使用口服药者中MD为-3.22 mmol/mol(-0.29%;95%CI -5.39, -1.05,p=0.004,I²=0%)。
- rtCGM的效应趋势大于isCGM:rtCGM的MD为-3.95 mmol/mol(-0.36%;95%CI -5.46至-2.44,p<0.00001,I²=0%),isCGM的MD为-1.79 mmol/mol(-0.16%;95%CI -5.28, 1.69,p=0.31,I²=64%)。
- CGM与范围内时间(TIR)增加6.36%(95%CI +2.48, +10.24,p=0.001,I²=9%)相关,与低于范围时间(TBR)降低0.66%(95%CI -1.21, -0.12,p=0.02,I²=45%)、高于范围时间(TAR)降低5.86%(95%CI -10.88, -0.84,p=0.02,I²=37%)及血糖变异性降低1.47%(95%CI -2.94, -0.01,p=0.05,I²=0%)相关。
- 与SMBG相比,CGM使用在严重低血糖发生率(RR 0.66,95%CI 0.15, 3.00,p=0.57,I²=0%)和大血管并发症(RR 1.54,95%CI 0.42, 5.72,p=0.52,I²=29%)上差异未达统计学显著;无试验报告微血管并发症数据。
局限性
- 所有研究均为开放标签。
- 严重低血糖及微血管和大血管并发症的发生数据稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Continuous glucose monitoring (CGM) is increasingly used in the treatment of type 2 diabetes, but the effects on glycaemic control are unclear. The aim of this systematic review and meta-analysis is to provide a comprehensive overview of the effect of CGM on glycaemic control in adults with type 2 diabetes. METHODS: We performed a systematic review using Embase, MEDLINE, Web of Science, Scopus and ClinicalTrials.gov from inception until 2 May 2023. We included RCTs investigating real-time CGM (rtCGM) or intermittently scanned CGM (isCGM) compared with self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes. Studies with an intervention duration <6 weeks or investigating professional CGM, a combination of CGM and additional glucose-lowering treatment strategies or GlucoWatch were not eligible. Change in HbA1c and the CGM metrics time in range (TIR), time below range (TBR), time above range (TAR) and glycaemic variability were extracted. We evaluated the risk of bias using the Cochrane risk-of-bias tool version 2. Data were synthesised by performing a meta-analysis. We also explored the effects of CGM on severe hypoglycaemia and micro- and macrovascular complications. RESULTS: We found 12 RCTs comprising 1248 participants, with eight investigating rtCGM and four isCGM. Compared with SMBG, CGM use (rtCGM or isCGM) led to a mean difference (MD) in HbA1c of -3.43 mmol/mol (-0.31%; 95% CI -4.75, -2.11, p<0.00001, I2=15%; moderate certainty). This effect was comparable in studies that included individuals using insulin with or without oral agents (MD -3.27 mmol/mol [-0.30%]; 95% CI -6.22, -0.31, p=0.03, I2=55%), and individuals using oral agents only (MD -3.22 mmol/mol [-0.29%]; 95% CI -5.39, -1.05, p=0.004, I2=0%). Use of rtCGM showed a trend towards a larger effect (MD -3.95 mmol/mol [-0.36%]; 95% CI -5.46 to -2.44, p<0.00001, I2=0%) than use of isCGM (MD -1.79 mmol/mol [-0.16%]; 95% CI -5.28, 1.69, p=0.31, I2=64%). CGM was also associated with an increase in TIR (+6.36%; 95% CI +2.48, +10.24, p=0.001, I2=9%) and a decrease in TBR (-0.66%; 95% CI -1.21, -0.12, p=0.02, I2=45%), TAR (-5.86%; 95% CI -10.88, -0.84, p=0.02, I2=37%) and glycaemic variability (-1.47%; 95% CI -2.94, -0.01, p=0.05, I2=0%). Three studies reported one or more events of severe hypoglycaemia and macrovascular complications. In comparison with SMBG, CGM use led to a non-statistically significant difference in the incidence of severe hypoglycaemia (RR 0.66, 95% CI 0.15, 3.00, p=0.57, I2=0%) and macrovascular complications (RR 1.54, 95% CI 0.42, 5.72, p=0.52, I2=29%). No trials reported data on microvascular complications. CONCLUSIONS/INTERPRETATION: CGM use compared with SMBG is associated with improvements in glycaemic control in adults with type 2 diabetes. However, all studies were open label. In addition, outcome data on incident severe hypoglycaemia and incident microvascular and macrovascular complications were scarce. REGISTRATION: This systematic review was registered on PROSPERO (ID CRD42023418005).
引用
- Jancev M, Vissers TACM, Visseren FLJ, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2024. PMID: 38363342. doi:10.1007/s00125-024-06107-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。